Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Viking Therapeutics has reported promising phase I data for their oral weight loss drug, VK2735, with patients on 100-miligram doses losing 8.2% of their body weight after 28 days. Jefferies analyst Roger Song described the results as "class-leading." In other news, Biontech exceeded expectations in the third quarter due to the early approval of its updated COVID-19 vaccine, while Novo Nordisk signed a $285 million deal with Ascendis to develop novel GLP-1 candidates. Additionally, there is growing interest in using CAR T therapies for autoimmune diseases, with researchers exploring whether these treatments can be repurposed to treat conditions like lupus and myasthenia gravis. Multiple companies are investigating the potential of these therapies in combating misdirected immune responses.